Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973891 | 0.81 | ALDH1A1 (0.35) | MAPK1ALDH1A1TSHRTDP1LMNA | |
| SCHEMBL183654 | 0.79 | — | — | |
| SCHEMBL562764 | 0.78 | — | — | |
| SCHEMBL15939627 | 0.76 | HAO1 (0.45) | HAO1OR51E2MAPK1ALDH1A1TSHR | |
| SCHEMBL27509208 | 0.76 | — | — | |
| Water SCHEMBL6078515 | 0.76 | — | — | |
| SCHEMBL101280 | 0.74 | — | — | |
| Benzene SCHEMBL6429767 | 0.73 | LMNA (0.37) | MAPK1ALDH1A1TSHRALOX15HSD17B10 | |
| SCHEMBL8966176 | 0.72 | — | — | |
| SCHEMBL1417102 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548509-B2 | For diagnosis and therapy of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety | NEUROGEN CORPORATION | 2003-04-15 | — | — | US | disclosed |
| EP-0960110-B8 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | YUAN JUN (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0960110-B1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6211187-B1 | POST-TRAUMATIC STRESS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0960110-A1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998029413-A1 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5723608-A | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | CRH, CRHR1, CRHR2 | HAO1 850/4885OR51E2 346/4885MAPK1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.